Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : COMPUTERIZED THERMAL IMAGING (COII)- research only -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (131)	5/28/1999 1:56:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 256

Computerized Thermal Imaging Retains Battelle Medical Products to Facilitate Submission of Data to FDA OGDEN, Utah, May 27, 1999 (PRIMEZONE) -- Computerized Thermal Imaging, Inc. (OTC BB: COII) (CTI), said today that it has retained the services of Battelle Medical Products, a leading provider of comprehensive product development services to the medical industry, to assist CTI with the formal FDA approval process for the Company's Thermal Breast Imaging System. "We decided to retain the services of Battelle Medical Products because there is nothing more critical for this company than to successfully complete the submission of clinical data to the FDA as quickly and expeditiously as possible," said David A. Packer, CTI's president. "Battelle is one of the most respected technology companies in the world, having delivered technology-based value to industry and government for nearly 70 years. We believe that by having them as part of our team, we will be able to avoid many of the pitfalls that might cause unanticipated delays in the approval process." "We are very impressed with the technology that CTI has developed and have already begun to assist them in preparing the clinical data for submission," said Rich Rosen, V.P., & General Manager for Battelle Medical Products. "We believe that CTI's Thermal Breast Imaging System represents a significant development in the early diagnosis of breast cancer. It may also have potential for reducing the costs and trauma of the disease." CTI is currently seeking FDA approval for its Thermal Breast Imaging System as an adjunctive diagnostic test to mammogram and clinical examination for the detection of breast cancer. The system is currently undergoing multi-center clinical trials to test its efficacy in differentiating benign from malignant breast abnormalities. The system uses a sophisticated heat sensitive camera to record thermal images of breast tissue. These images are then processed with a proprietary computer algorithm designed to recognize the distinct heat signatures of benign and malignant tissue. The test is simple, painless, and requires no exposure to radiation or heat compression. Computerized Thermal Imaging, Inc. develops and deploys thermal imaging and associated technologies for use in the enhancement of medical screening, diagnosis and patient management. More information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at (801) 776-4700.